Atrium Therapeutics has now collected $30 million in milestone payments from Bristol Myers Squibb in under four months, and the second $15 million installment arrived the same week the company opened enrollment in its first-ever clinical trial. That timing is not coincidental. The BMS collaboration funds the runway, but the Corventis Phase 1/2 study in PRKAG2 syndrome is the program that will determine whether Atrium’s RNA delivery platform earns the credibility it needs to justify the rest of the pipeline.
PRKAG2 syndrome is a rare autosomal dominant cardiomyopathy caused by mutations in the PRKAG2 gene, producing hyperactive AMPK signaling, pathological glycogen accumulation in cardiac tissue, ventricular hypertrophy, and arrhythmias. The disease is managed largely with supportive care and device therapy. ATR 1072, now Atrium’s first precision cardiology candidate to enter the clinic, targets the underlying genetic driver with an siRNA delivered via a platform originally designed at Avidity Biosciences that pairs the tissue selectivity of monoclonal antibodies with oligonucleotide precision. The Corventis trial is structured across two parts: a multiple ascending dose segment to establish safety and identify the recommended Phase 2 dose, followed by a single-arm expansion cohort to evaluate efficacy trends in cardiac structure and function across approximately 37 participants total. FDA cleared the IND, Health Canada issued a No Objection Letter, and Atrium expects to dose the first participant before year-end.
The financial picture is tight but deliberate. Q2 R&D spend of $15.3 million reflects clinical preparations and IND-enabling work, against just $3.0 million in collaboration revenue for the quarter. G&A of $10.3 million signals a company that has already built out its operating infrastructure. The $263.9 million cash position, supplemented by the second BMS milestone payment earned in August, buys the company runway through mid-2028. That covers the proof-of-concept Corventis readout expected in the second half of 2027 and the planned IND filing for ATR 1086, targeting phospholamban cardiomyopathy, also in 2027. Two additional undisclosed rare cardiomyopathy programs are in earlier stages, with a next development candidate selection targeted for the same year.
The single number that will define Atrium’s near-term credibility is the Corventis proof-of-concept dataset in the second half of 2027. If cardiac structural and functional endpoints move in Part B, the platform claim of efficient, selective siRNA delivery to heart tissue gains real clinical evidence. If they do not, three subsequent pipeline programs and a BMS collaboration built on the same delivery technology all face the same question at once.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
